Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Bergenbio Asa LSE:0RU5 London Ordinary Share NO0010650013 BERGENBIO ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 46.00 0.00 0.00 0.00 0.00 0.00 178 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

BerGenBio ASA: Invitation to First Quarter 2020 Results Webcast Presentation

13/05/2020 6:23am

PR Newswire (US)


Bergenbio Asa (LSE:0RU5)
Historical Stock Chart


From May 2020 to Jul 2020

Click Here for more Bergenbio Asa Charts.

BERGEN, Norway, May 13, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), will announce its results for the first quarter 2020 on Tuesday 19 May 2020. A webcast presentation by BerGenBio's senior management team will take place at 10 am CET.

The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Financial Reports. A recording will be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in the section: Investors/Financial Reports from 7:00 am CET the same day.

About BerGenBio

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad Phase II oncology clinical development programme focused on combination and single agent therapy in lung cancer and leukaemia. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing Phase I clinical testing. In parallel, BerGenBio is developing a companion diagnostic test to identify those patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO).

For more information, please contact:

Richard Godfrey
CEO, BerGenBio ASA
+47-917-86-304

Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47-917-86-513

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone, Carina Jurs,
Consilium Strategic Communications
bergenbio@consilium-comms.com
+44-20-3709-5700

Media Relations in Norway

Jan Petter Stiff, Crux Advisers
stiff@crux.no
+47-995-13-891

For more information, visit www.bergenbio.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bergenbio-asa/r/bergenbio-asa--invitation-to-first-quarter-2020-results-webcast-presentation,c3110120

 

Copyright 2020 PR Newswire

1 Year Bergenbio Asa Chart

1 Year Bergenbio Asa Chart

1 Month Bergenbio Asa Chart

1 Month Bergenbio Asa Chart
ADVFN Advertorial
Your Recent History
LSE
0RU5
Bergenbio ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200706 18:46:20